US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.
HealthDay on MSN1d
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for NowOn October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...
The Food and Drug Administration (FDA) on Friday declared shortages of three intravenous drugs produced at a North Carolina ...
Forty years after the Hatch-Waxman Act created a market for affordable generic versions of prescription medications, ...
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...
Drug shortages that happen when demand surges can ... as compounded drugs are not FDA-approved and could have inconsistent potency. The FDA has issued warnings about the risks of compounded ...
Hurricane Helene damaged one of the major NC-based manufacturing facilities of IV fluids. What’s being done to help hospitals ...
The shortage of pediatric cancer drugs is a growing concern for families and healthcare providers, with critical medications, like injectable methotrexate and leucovrin, increasingly hard to obtain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback